Sign inCreate account

Report workspace

Add to folder
NCT00388180COMPLETEDanonymous

A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Peroxisome proliferator-activated receptors (PPARs)

Indication / condition

AI-normalized

Hypercholesterolemia

Intervention

Source record

GW501516, GW590735

Source & freshness

Source record

NCT ID

NCT00388180

Original source

ClinicalTrials.gov

Source last updated

Mar 19, 2012

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00388180

Title

A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase 2

Condition raw

Hypercholesterolemia, Dyslipidaemias, Obesity

Condition normalized

Hypercholesterolemia, Dyslipidaemias, Obesity

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Peroxisome proliferator-activated receptors (PPARs)

Target normalized

Peroxisome proliferator-activated receptors (PPARs)

Interventions

GW501516, GW590735

Public preview

Source record

The study evaluates GW590735X and GW501516X, both PPAR agonists, for their potential to reduce adiposity and inflammation in overweight and obese individuals. Given the rising prevalence of obesity and related metabolic disorders, successful outcomes could position GSK favorably in the obesity and dyslipidemia markets. However, competition from existing therapies and emerging candidates targeting similar pathways necessitates careful market positioning and differentiation strategies. The results may also influence GSK's pipeline strategy and partnerships in metabolic disease management.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT00388180

Status

COMPLETED

Phase

Phase 2

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

The study evaluates GW590735X and GW501516X, both PPAR agonists, for their potential to reduce adiposity and inflammation in overweight and obese individuals. Given the rising prevalence of obesity and related metabolic disorders, successful outcomes could position GSK favorably in the obesity and dyslipidemia markets. However, competition from existing therapies and emerging candidates targeting similar pathways necessitates careful market positioning and differentiation strategies. The results may also influence GSK's pipeline strategy and partnerships in metabolic disease management.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 19, 2012
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00388180

Indication

Hypercholesterolemia

Modality

small molecule

Target

Peroxisome proliferator-activated receptors (PPARs)

Intervention

GW501516, GW590735

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.